Lim, L., Machingura, A., Taye, M., Pe, M., Coens, C., Martinelli, F., Alanya, A., Antunes, S., Tu, D., Basch, E., Ringash, J., Brandberg, Y., Groenvold, M., Eggermont, A., Cardoso, F., Van Meerbeeck, J., Koller, M., Van der Graaf, W. T. A., Taphoorn, M. J. B., Koekkoek, J. A. F., Reijneveld, J. C., Soffietti, R., Velikova, G, Bottomley, A., Flechtner, H., & Musoro, J. Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: A validation study. eClinicalMedicine, (2025), 82, 103153.

2. Tur P, Oldenburger E, Bottomley A, Cella D, Lee SF, Chan AW, Marta GN, Jacobs T, Chow E, Wong HCY, Rembielak A. Evaluation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care and the Functional Assessment of Chronic Illness Therapy-Palliative in assessing the quality of life in patients with advanced cancer. Curr Opin Support Palliat Care. 2025 Mar 12. doi: 10.1097/SPC.0000000000000750. PMID: 40072452.

3. Bjelic-Radisic V, Cardoso F, Weis J, Pogoda K, Arraras JI, Greimel E, Bottomley A, Cameron D, Brain E, Hartup S, Da Costa Vieira RA, Hoefnagels N, Huang CS, Shamieh O, Pinto M, Belay YB, Serpentini S, Bleiker E, Nookala M, Shimomura A, Sturm-Inwald E, Getu MA, Bliem B, Astrup G, Morag O, Kikawa Y, Kuljanic K, Nevries N, Sprangers M, Aaronson N, Sinai P, Tomaszweski K, Galalae R, Conroy T, Duhoux F, Chie WC, Velikova G; EORTC Quality of Life Group and Breast Cancer Group. An international Phase IV field study – psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42. Breast. 2025 Jan 27;80:103890. doi: 10.1016/j.breast.2025.103890. Epub ahead of print. PMID: 39947087.

4. Seyringer, S., Pilz, M. J., Jansen, F., Büttner, M., King, M. T., Norman, R., Kemmler, G., Nerich, V., Holzner, B., Bottomley, A., & Gamper, E. M. (2025). Cancer-specific utility instrument for health economic evaluations: A synopsis of the EORTC QLU-C10D user manual and current validity evidence. European Journal of Cancer, 217, 115235.

5. Ignacio JA, Illarramendi JJ, Manterola A, Zarandona U, Ibañez B, Bottomley A, Visus A, Teijeira L, Cruz S, Barrado M, Vera M. Quality of life of patients treated for stage IV breast cancer. Multidimensional assessment and examination of determining factors Contemp Oncol (Pozn) 2024; 28 (4): 1–8, doi.org/10.5114/wo.2024.147006

6. Seyringer, S., Pilz, M. J., Bottomley, A., King, M. T., Norman, R., Gamper, E. M., & EORTC Quality of Life Group (2024). Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma. The European Journal of Health Economics: HEPAC: Health Economics in Prevention & Care, 10.1007/s10198-024-01729-4. doi.org/10.1007/s10198-024-01729-4

7. Hircock, C., Wang, A. J., Goonaratne, E., Sferrazza, D., Bottomley, A., Cella, D., Lee, S. F., Chan, A. W., Chow, E., & Wong, H. C. Y. (2024). Comparing the EORTC QLQ-LC13, EORTC QLQ-LC29, and the FACT-L for assessment of quality of life in patients with lung cancer – an updated systematic review. Current opinion in supportive and palliative care, 10.1097/SPC.0000000000000725.

8. Wang, A. J., Hircock, C., Sferrazza, D., Goonaratne, E., Cella, D., Bottomley, A., Lee, S. F., Chan, A., Chow, E., & Wong, H. C. Y. (2024). The EORTC QLQ breast modules and the FACT-B for assessing quality of life in breast cancer patients – an updated literature review. Current opinion in supportive and palliative care, 18(4): p 249-259, December 2024.10.1097/SPC.0000000000000724.

9. Cleeland CS, Keating KN, Cuffel B, Elbi C, Siegel JM, Gerlinger C, Symonds T, Sloan JA, Dueck AC, Bottomley A, Wang XS, Williams LA, Mendoza TR. Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma. Sci Rep. 2024 Jun 27;14(1):14839. doi: 10.1038/s41598-024-62307-5. PMID: 38937473; PMCID: PMC11211485.

10. Pilz MJ, Seyringer S, Al-Naesan I, King MT, Bottomley A, Norman R, Schlosser L, Hell T, Gamper EM. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs. Pharmacoecon Open. 2024 May 2. doi: 10.1007/s41669-024-00484-9. Epub ahead of print. PMID: 38696019.

11. Pilz MJ, Seyringer S, Hallsson LR, Bottomley A, Jansen F, King MT, Norman R, Rutten MJ, Leeuw IMV, Siersema PD, Gamper EM. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands. Eur J Health Econ. 2024 Mar 14. doi: 10.1007/s10198-024-01670-6. Epub ahead of print. PMID: 38483665.

12. Aiyegbusi, O.L., Cruz Rivera, S., Roydhouse, J. Kamudoni, YA., Anderson N, Baldwin RM, Bhatnagar V, Black J, Bottomley A, Brundage M, Cella D, Collis P, Davies EH, Denniston AK, Gardner A, Gnanasakthy A, Golub RM, Hughes SE, Jeyes F, Kern S, King-Kallimanis BL, Martin A, McMullan K, Mercieca-Bebber R, Monteiro J, Peipert JD, Quijano-Campos JC, Quinten C, Regnault A, Sasseville M, Snyder C, Stover AM, Verdi R, Wilson R &. Calvert MJ. Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med 30, 650–659, 2024.doi.org/10.1038/s41591-024-02827-9

13. Reijneveld JC, Machingura A, Coens C, Taphoorn MJB, Taal W, Clement PM, Idbaih A, de Vos FYF, Klein M, Wick W, Mulholland PJ, Lewis J, Golfinopoulos V, Ghislain I, Bottomley A, van den Bent MJ; EORTC Brain Tumor Group. Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091). Eur J Cancer. 2023 Jun 19;190:112946. doi: 10.1016/j.ejca.2023.112946. PMID: 37453240.

14. Caramanna I, Reijneveld JC, van de Ven PM, van den Bent M, Idbaih A, Wick W, Taphoorn MJB, Dirven L, Bottomley A, Klein M; EORTC Quality of Life Group and EORTC Brain Tumor Group. Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials Eur J Cancer. 2023 Jun;186:38-51. doi: 10.1016/j.ejca.2023.02.029.

15. Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O’Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A; SISAQOL-IMI Consortium. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. Lancet Oncol. 2023 Jun;24(6):e270-e283. doi: 10.1016/S1470-2045(23)00157-2.PMID: 37269858

16. Musoro JZ, Coens C, Sprangers MAG, Brandberg Y, Groenvold M, Flechtner HH, Cocks K, Velikova G, Dirven L, Greimel E, Singer S, Pogoda K, Gamper EM, Sodergren SC, Eggermont A, Koller M, Reijneveld JC, Taphoorn MJB, King MT, Bottomley A; EORTC Melanoma, Breast, Head and Neck, Genito-urinary, Gynecological, Gastro-intestinal, Brain, Lung and Quality of Life Groups. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types. Eur J Cancer. 2023 Jul;188:171-182. doi: 10.1016/j.ejca.2023.04.027.

17. Piccinin C, Basch E, Bhatnagar V, Calvert M, Campbell A, Cella D, Cleeland CS, Coens C, Darlington AS, Dueck AC, Groenvold M, Herold R, King-Kallimanis BL, Kluetz PG, Kuliś D, O’Connor D, Oliver K, Pe M, Reeve BB, Reijneveld JC, Wang XS, Bottomley A. Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group. Lancet Oncol. 2023 Feb;24(2):e86-e95. doi: 10.1016/S1470-2045(22)00654-4.

18. Pilz MJ, Nolte S, Liegl G, King M, Norman R, McTaggart-Cowan H, Bottomley A, Rose M, Kemmler G, Holzner B, Gamper EM; EORTC Quality of Life Group. The EORTC QLU-C10D – development and investigation of general population utility norms for Canada, France, Germany, Italy, Poland and the U.K; Value Health. 2022 Dec 23:S1098-3015(22)04783-0. doi: 10.1016/j.jval.2022.12.009.

19. Oosting SF, Barriuso J, Bottomley A, Galotti M, Gyawali B, Kiesewetter B, Latino NJ, Martinelli F, Pe M, Pentheroudakis G, Roitberg F, Vachon H, de Vries EGE, Piccart M, Cherny NI; ESMO-MCBS Working Group and Extended Working Group. Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit; Ann Oncol. 2022 Dec 19:S0923-7534(22)04772-X. doi: 10.1016/j.annonc.2022.12.004.

20. Cocks K, Wells JR, Johnson C, Schmidt H, Koller M, Oerlemans S, Velikova G, Pinto M, Tomaszewski KA, Aaronson NK, Exall E, Finbow C, Fitzsimmons D, Grant L, Groenvold M, Tolley C, Wheelwright S, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life; Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer; Eur J Cancer. 2023 Jan;178:128-138. doi: 10.1016/j.ejca.2022.10.026. Epub 2022 Nov 1.

21. Amdal CD, Falk RS, Singer S, Pe M, Piccinin C, Bottomley A, Appiah LT, Arraras JI, Bayer O, Buanes EA, Darlington AS, Arbanas GD, Hofsø K, Holzner B, Sahlstrand-Johnson P, Kuliś D, Parmar G, Rmeileh NMEA, Schranz M, Sodergren S, Bjordal K. A multicenter international prospective study of the validity and reliability of a COVID-19-specific health-related quality of life questionnaire; Qual Life Res, 2022 Oct 23. doi: 10.1007/s11136-022-03272-2.

22. Caramanna I, Klein M, van den Bent M, Idbaih A, Wick W, Taphoorn MJB, Dirven L, Bottomley A, Reijneveld JC; EORTC Quality of Life Group and EORTC Brain Tumor Group. Neurocognitive impairment and patient-proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients; Qual Life Res. 2022 Aug 18.doi: 10.1007/s11136-022-03197-w.

23. Gilbert A, Piccinin C, Velikova G, Groenvold M, Kuliś D, Blazeby JM, Bottomley A. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events; J Clin Oncol. 2022 Aug 16;JCO2102017. doi: 10.1200/JCO.21.02017

24. Koller M, Musoro JZ, Tomaszewski K, Coens C, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A. Corrigendum to “Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials” [Lung Cancer 167C (2022) 65-72]; Lung Cancer. 2022 Sep;171:126. doi: 10.1016/j.lungcan.2022.05.006. Epub 2022 May 20.

25. Cruz Rivera S, Aiyegbusi OL, Ives J, Draper H, Mercieca-Bebber R, Ells C, Hunn A, Scott JA, Fernandez CV, Dickens AP, Anderson N, Bhatnagar V, Bottomley A, Campbell L, Collett C, Collis P, Craig K, Davies H, Golub R, Gosden L, Gnanasakthy A, Haf Davies E, von Hildebrand M, Lord JM, Mahendraratnam N, Miyaji T, Morel T, Monteiro J, Zwisler AO, Peipert JD, Roydhouse J, Stover AM, Wilson R, Yap C, Calvert MJ. Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics Guidelines, JAMA. 2022 May 17;327(19):1910-1919. doi: 10.1001/jama.2022.6421.

26. Machingura A, Taye M, Musoro J, Ringash J, Pe M, Coens C, Martinelli F, Tu D, Basch E, Brandberg Y, Grønvold M, Eggermont A, Cardoso F, Van Meerbeeck J, van der Graaf WTA, Taphoorn M, Reijneveld JC, Soffietti R, Sloan J, Velikova G, Flechtner H, Bottomley A; EORTC Quality of Life Group, Brain tumour, Breast Cancer, Melanoma Group, Lung Cancer, Soft Tissue and Bone Sarcoma, Lymphoma, Gastrointestinal Tract Cancer, Head and Neck Cancer, Genito-Urinary Cancers, and Gynecological Cancer Groups. Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. Eur J Cancer. 2022 May 12;170:1-9. doi: 10.1016/j.ejca.2022.03.039.

27. Koller M, Musoro JZ, Tomaszewski K, Coens C, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials; Lung Cancer. 2022 May;167:65-72. doi: 10.1016/j.lungcan.2022.03.018. Epub 2022 Mar 29.

28. Coomans M, Dirven L, Aaronson N, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB; EORTC Quality of Life Group and the EORTC Brain Tumor Group. Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period; Neuro Oncol. 2022 Apr 11:noac097. doi: 10.1093/neuonc/noac097.

29. Amdal CD, Taylor K, Kuliś D, Falk RS, Bottomley A, Arraras JI, Barte JH, Darlington AS, Hofsø K, Holzner B, Jørgensen NMH, Mariano MP, Pe M, Piccinin C, Riccetti N, Schranz M, Wheelwright S, Bjordal K. Health-related quality of life in patients with COVID-19; international development of a patient-reported outcome measure, J Patient Rep Outcomes. 2022 Mar 26;6(1):26. doi: 10.1186/s41687-022-00434-1.

30. Dal Lago L, Uwimana AL, Coens C, Vuylsteke P, Curigliano G, Brouwers B, Jagiello-Gruszfeld A, Altintas S, Tryfonidis K, Poncet C, Bottomley A, Sousa B, Brain E, Wildiers H; Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial; J Geriatr Oncol. 2022 Jan 28:S1879-4068(22)00010-8. doi: 10.1016/j.jgo.2022.01.009.

31. Snyder C, Crossnohere N, King M, Reeve BB, Bottomley A, Calvert M, Thorner E, Wu AW, Brundage M; The PROTEUS-Trials Consortium: Optimizing the use of patient-reported outcomes in clinical trials. PROTEUS-Trials Consortium. Clin Trials. 2022 Jan 31:17407745221077691. doi: 10.1177/17407745221077691.

32. Dal Lago L, Uwimana AL, Coens C, Vuylsteke P, Curigliano G, Brouwers B, Jagiello-Gruszfeld A, Altintas S, Tryfonidis K, Poncet C, Bottomley A, Sousa B, Brain E, Wildiers H. Share; Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. J Geriatr Oncol. 2022 Jan 28:S1879-4068(22)00010-8. doi: 10.1016/j.jgo.2022.01.009.

33. Sztankay M, Wintner LM, Roggendorf S, Nordhausen T, Dirven L, Taphoorn MJB, Leeuw IMV, Velikova G, Bottomley A, Kulis D, Kachel T, Schmidt H; EORTC Quality of Life Group. Developing an e-learning course on the use of PRO measures in oncological practice: health care professionals’ preferences for learning content and methods Support, Care Cancer. 2021 Nov 19. doi: 10.1007/s00520-021-06676-x.

34. Koller M, Müller K, Nolte S, Schmidt H, Harvey C, Mölle U, Boehm A, Engeler D, Metzger J, Sztankay M, Holzner B, Groenvold M, Kuliś D, Bottomley A; EORTC Quality of Life Group. Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey, Health Qual Life Outcomes. 2021 Oct 9;19(1):235. doi: 10.1186/s12955-021-01866-x.

35. Gamper EM, Musoro JZ, Coens C, Stelmes JJ, Falato C, Groenvold M, Velikova G, Cocks K, Flechtner HH, King MT, Bottomley A; EORTC Genito-Urinary Tract Cancer Group and Quality of Life Groups. Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials, BMC Cancer. 2021 Oct 7;21(1):1083. doi: 10.1186/s12885-021-08609-7.

36. Piccinin C, Pe M, Kuliś D, Shaw JW, Wheelwright SJ, Bottomley A. Equivalence testing of a newly developed interviewer-led telephone script for the EORTC QLQ-C30, Qual Life Res. 2021 Jul 20. doi: 10.1007/s11136-021-02955-6.

37. Calvert M, King M, Mercieca-Bebber R, Aiyegbusi O, Kyte D, Slade A, Chan AW, Basch E, Bell J, Bennett A, Bhatnagar V, Blazeby J, Bottomley A, Brown J, Brundage M, Campbell L, Cappelleri JC, Draper H, Dueck AC, Ells C, Frank L, Golub RM, Griebsch I, Haywood K, Hunn A, King-Kallimanis B, Martin L, Mitchell S, Morel T, Nelson L, Norquist J, O’Connor D, Palmer M, Patrick D, Price G, Regnault A, Retzer A, Revicki D, Scott J, Stephens R, Turner G, Valakas A, Velikova G, von Hildebrand M, Walker A, Wenzel L. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials, BMJ Open. 2021 Jun 30;11(6):e045105. doi: 10.1136/bmjopen-2020-045105.

38. Amdal CD, Pe M, Falk RS, Piccinin C, Bottomley A, Arraras JI, Darlington AS, Hofsø K, Holzner B, Jørgensen NMH, Kulis D, Rimehaug SA, Singer S, Taylor K, Wheelwright S, Bjordal K. Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review, Qual Life Res. 2021 Jun 19:1-15. doi: 10.1007/s11136-021-02908-z.

39. Piccinin C, Bottomley A, Velikova G, Groenvold M, Kuliś D, Blazeby JM, Gilbert A, Coverage of symptomatic toxicities from the common terminology criteria for adverse events (CTCAE) framework within the european organization for research and treatment of cancer (EORTC) item library. Journal of Clinical Oncology 39, no. 15_suppl. 2021 May 28, doi: 10.1200/JCO.2021.39.15_suppl.e24117

40. Lehmann J, Holzner B, Giesinger JM, Bottomley A, Ansari S, von Butler L, Kemmler G. Functional health and symptoms in Spain before and during the COVID-19 pandemic, BMC Public Health. 2021 May 1;21(1):837. doi: 10.1186/s12889-021-10899-2.

41. Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12.

42. Dirven L, Musoro JZ, Coens C, Reijneveld JC, Taphoorn MJB, Boele FW, Groenvold M, van den Bent MJ, Stupp R, Velikova G, Cocks K, Sprangers MAG, King MT, Flechtner HH, Bottomley A. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients, Neuro Oncol. 2021 Feb 18:noab037. doi: 10.1093/neuonc/noab037.

43. Vachon H, Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Fortpied C, Flechtner HH, Vestmoe Maraldo M, Hutchings M, Meijnders P, Aleman B, Lugtenburg P, Spina M, André M, Hertzberg M, Briones J, Bottomley A, EORTC Quality of Life Group, Lymphoma Group, Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors, Eur J Haematol. 2021 May;106(5):697-707. doi: 10.1111/ejh.13601.

44. Sodergren SC, Wheelwright SJ, Fitzsimmons D, Efficace F, Sprangers M, Fayers P, Harle A, Schmidt H, Bottomley A, Darlington AS, Benson C, Bredart A, Hentschel L, Arraras JI, Ioannidis G, Leahy M, Lugowska I, Nicolatou-Galitis O, Petranovic D, Rohde GE, Vassiliou V, Johnson CD; EORTC Quality of Life Group. Developing symptom lists for people with cancer treated with targeted therapies, Target Oncol. 2021 Jan;16(1):95-107. doi: 10.1007/s11523-020-00769-z.

45. Coomans MB, Dirven L, Aaronson NK, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Sloan JA, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB, Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modelling, Neurooncol Adv. 2020 Oct 29;2(1):vdaa147. doi: 10.1093/noajnl/vdaa147

46. Caramanna I, Bottomley A, Drijver AJ, Twisk J, van den Bent M, Idbaih A, Wick W, Pe M, Klein M, Reijneveld JC, EORTC Quality of Life Group and Brain Tumour Group. Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials, Eur J Cancer. 2020 Dec 18;144:162-168. doi: 10.1016/j.ejca.2020.10.040.

47. Musoro JM, Coens C, Singer S, Tribius S, Oosting SF, Groenvold M, Simon C, Machiels JP, Grégoire V, Velikova G, Cocks K, Sprangers MAG, King MT, Bottomley A, EORTC Head and Neck and Quality of Life Groups; Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer; Head Neck. 2020 Nov;42(11):3141-3152.doi: 10.1002/hed.26363. Epub 2020 Jul 6.

48. Wintner L, Giesinger JM, Sztankay M, Bottomley A, Holzner B on behalf of the EORTC Quality of Life Group; Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial. Trials. 2020 Oct 13;21(1):849. doi: 10.1186/s13063-020-04745-w.

49. Terada M, Nakamura K, Martinelli F, Pe M, Mizusawa J, Eba J, Fukuda H, Kiyota N, Gatellier L, Majima Y, Velikova G, Bottomley A; Results from a 1-day workshop on the assessment of quality of life in cancer patients: a joint initiative of the Japan Clinical Oncology Group and the European Organisation for Research and Treatment of Cancer; Jpn J Clin Oncol. 2020 Oct 22;50(11):1333-1341. doi: 10.1093/jjco/hyaa119.

50. Fiero MH, Pe M, Weinstock C, King-Kallimanis BL, Komo S, Klepin HD, Gray SW, Bottomley A, Kluetz P, Sridhara R; Demystifying the estimand framework: a case study using patient-reported outcomes in oncology; The Lancet Oncology, Lancet Oncol. 2020 Oct;21(10):e488-e494. doi: 10.1016/S1470-2045(20)30319-3.